Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Pain management drugs are prescribed in serious to mild pain conditions such as back pain, neck pain, and pain from cancer. Pain management drugs market is highly lucrative due to low availability of alternative drug therapies for treatment of pain. Drug manufacturers are introducing effective generic version in various dosage forms, which is driving the market growth. Chronic pain is one of the highly prevalent pain disorders, which is primarily treated by these medications. The medical management of pain diseases is patient specific and is highly dependent on individual patients' symptoms.
Market Dynamics
The global pain management drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs such as OxyContin, Opana ER, and Celebrex have lost patent protection due to which generic manufacturers have developed generic version with product variations fostering growth of the pain management drugs market. Continuous requirement of the medication coupled with easy availability is expected to boost the adoption of pain drugs over the forecast period. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as cancer (leading to cancer pain) are fueling growth of the pain management drugs market. However, life threatening side effects associated with these medications, as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the pain management drugs market.
Key features of the study:
• This report provides in-depth analysis of pain management drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018-2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global pain management drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global pain management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pain management drugs market
Detailed Segmentation:
• Global Pain Management Drugs Market, by Drug Class:
o Opioids
o NSAIDs
o Anticonvulsants
o Antidepressants
o Others
• Global Pain Management Drugs Market, by Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Pain Management Drugs Market, by Region:
o North America
o By Drug Class:
o Opioids
o NSAIDs
o Anticonvulsants
o Antidepressants
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o U.S.
o Canada
o Europe
o By Drug Class:
o Opioids
o NSAIDs
o Anticonvulsants
o Antidepressants
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o By Drug Class:
o Opioids
o NSAIDs
o Anticonvulsants
o Antidepressants
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o By Drug Class:
o Opioids
o NSAIDs
o Anticonvulsants
o Antidepressants
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o Brazil
o Mexico
o Rest of Latin America
o Middle East
o By Drug Class:
o Opioids
o NSAIDs
o Anticonvulsants
o Antidepressants
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o GCC
o Israel
o Rest of Middle East
o Africa
o By Drug Class:
o Opioids
o NSAIDs
o Anticonvulsants
o Antidepressants
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o Central Africa
o South Africa
o North Africa
• Company Profiles
o Pfizer, Inc.*
o Company Overview
o Product Portfolio
o Financial Performance
o Key Strategies
o Recent Developments
o Sanofi S.A.
o Mylan N.V.
o Teva Pharmaceutical Industries Ltd.
o Eli Lilly and Company
o Abbott Laboratories
o Purdue Pharma L.P.
o GlaxoSmithKline Plc
o Johnson & Johnson
o F. Hoffmann La Roche Ltd.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Drug Class
o Market Snippet, By Distribution Channel
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o PEST Analysis
o PORTER's Analysis
o Regulatory Scenario
4. Global Pain Management Drugs Market, By Drug Class, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Opioids
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o NSAIDs
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Anticonvulsants
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Antidepressants
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Muscle Relaxants
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
5. Global Pain Management Drugs Market, By Distribution Channel, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, 2016-2026
o Segment Trends
o Hospital Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Retail Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Online Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
6. Global Pain Management Drugs Market, By Regions, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, By Region, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, For Regions, 2017-2026
o North America
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o U.S.
o Canada
o Europe
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of APAC
o Latin America
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Africa
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o Central Africa
o South Africa
o North Africa
o Middle East
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o GCC
o Israel
o Rest of Middle East
7. Competitive Landscape
o Company Profiles
o Pfizer, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Sanofi S.A.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Mylan N.V.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Teva Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Eily, Lilly, and Company
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Abbott Laboratories
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Purdue Pharma L.P.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o GlaxoSmithKline Plc
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Johnson & Johnson
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o F. Hoffmann La Roche Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
8. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 34 market data tables and 55 figures on "Pain Management Drugs Market - Global forecast to 2026".
